MoonLake Immunotherapeutics, a clinical-stage biotechnology company, focuses on developing therapies for inflammatory skin and joint diseases. It develops Sonelokimab, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody for the treat...
Q1 2026
May 11, 2026
FY 2025
Feb 25, 2026
Q4 2025
Q3 2025
Nov 5, 2025
Q2 2025
Aug 5, 2025
